The following chapter outlines current liver-directed therapeutic options for metastatic neuroendocrine tumors, provides an overview of the general properties of neuroendocrine neoplasms and the associated carcinoid syndrome, discusses the advent of peptide receptor radionuclide therapy and its effect on the treatment paradigm for liver-dominant disease, and examines potential future management strategies.